<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ERY-TAB- erythromycin tablet, delayed release </strong><br>Carilion Materials Management<br></p></div>
<h1>ERY-TAB (ERYTHROMYCIN DELAYED-RELEASE TABLETS, USP) ENTERIC-COATED
        <span class="Sup">®</span><br><br><br>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Rx only</span></p>
<p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of ERY-TAB and other antibacterial drugs, ERY-TAB should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.
                            <span class="Sup">®</span><span class="Sup">®</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">ERY-TAB (erythromycin delayed-release tablets) is an antibacterial product containing erythromycin base in a specially enteric-coated tablet. The coating protects the antibiotic from the inactivating effects of gastric acidity and permits efficient absorption of the antibiotic in the small intestine. ERY-TAB tablets for oral administration are available in three dosage strengths, each white oval tablet containing either 250 mg, 333 mg, or 500 mg of erythromycin as the free base. ERY-TAB tablets comply with
                            <span class="Sup">®</span><span class="Sup">®</span><span class="Sup">®</span><span class="Italics">USP Dissolution Test 1.</span></p>
<p>Erythromycin is produced by a <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> of (formerly ) and belongs to the macrolide group of antibiotics. It is basic and readily forms salts with acids. Erythromycin is a white to off-white powder, slightly soluble in water, and soluble in alcohol, chloroform, and ether. Erythromycin is known chemically as (3R*, 4S*, 5S*, 6R*, 7R*, 9R*, 11R*, 12R*,13S*, 14R*)-4-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α -L- -hexopyranosyl)oxy]-14-ethyl-7,12,13-trihdroxy-3,5,7,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-(dimethylamino)-β-D- -hexopyranosyl]oxy]oxacyclotetradecane-2,10-dione. The molecular formula is C H NO , and the molecular weight is 733.94. The structural formula is:
                            <span class="Italics">Saccharopolyspora erythraea</span><span class="Italics">Streptomyces erythraeus</span><span class="Italics">ribo</span><span class="Italics">xylo</span><span class="Sub">37</span><span class="Sub">67</span><span class="Sub">13</span></p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=83b88647-1b7c-444f-ab20-cdb5afd265bf&amp;name=ery-tab-01.jpg"></div>
<p><span class="Bold">Inactive Ingredients</span></p>
<p>Ammonium hydroxide, colloidal silicon dioxide, croscarmellose sodium, crospovidone, diacetylated monoglycerides, hydroxypropyl cellulose, hypromellose, hypromellose phthalate, magnesium stearate, microcrystalline cellulose, povidone, propylene glycol, sodium citrate, sorbitan monooleate, talc, and titanium dioxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="CP"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Orally administered erythromycin base and its salts are readily absorbed in the microbiologically active form. Interindividual variations in the absorption of erythromycin are, however, observed, and some patients do not achieve optimal serum levels. Erythromycin is largely bound to plasma proteins. After absorption, erythromycin diffuses readily into most body fluids. In the absence of meningeal <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, low concentrations are normally achieved in the spinal fluid but the passage of the drug across the blood-brain barrier increases in <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>. Erythromycin crosses the placental barrier, but fetal plasma levels are low. The drug is excreted in human milk. Erythromycin is not removed by peritoneal dialysis or hemodialysis.</p>
<p>In the presence of normal hepatic function, erythromycin is concentrated in the liver and is excreted in the bile; the effect of hepatic dysfunction on biliary excretion of erythromycin is not known. After oral administration, less than 5% of the administered dose can be recovered in the active form in the urine.</p>
<p>ERY-TAB tablets are coated with a polymer whose dissolution is pH dependent. This coating allows for minimal release of erythromycin in acidic environments, e.g., stomach. The tablets are designed for optimal drug release and absorption in the small intestine. In multiple-dose, steady-state studies, ERY-TAB tablets have demonstrated adequate drug delivery in both fasting and non-fasting conditions. Bioavailability data are available.
                            <span class="Sup">®</span><span class="Sup">®</span></p>
<div class="Section" data-sectionCode="49489-8">
<a name="section-3.1"></a><p></p>
<h2>Microbiology</h2>
<div class="Section" data-sectionCode="43679-0">
<a name="section-3.1.1"></a><p></p>
<h3>Mechanism of Action</h3>
<p class="First">Erythromycin acts by inhibition of protein synthesis by binding 50S ribosomal subunits of susceptible organisms. It does not affect nucleic acid synthesis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.2"></a><p></p>
<h3>Mechanism of Resistance</h3>
<p class="First">The major route of resistance is modification of the 23S rNA in the 50S ribosomal subunit to insensitivity while efflux can also be significant.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.3"></a><p></p>
<h3>Interactions with Other Antibiotics</h3>
<p class="First">Antagonism exists between erythromycin and clindamycin, lincomycin, and chloramphenicol.
                                            <span class="Italics">in vitro</span></p>
<p>Erythromycin has been shown to be active against most isolates of the following bacteria both and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in the section.
                                            <span class="Italics">in vitro</span><span class="Bold">INDICATIONS AND USAGE</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.4"></a><p></p>
<h3>Gram-positive Bacteria</h3>
<dl>
<dt> </dt>
<dd><span class="Italics">Corynebacterium diphtheriae</span></dd>
<dt> </dt>
<dd><span class="Italics">Corynebacterium minutissimum</span></dd>
<dt> </dt>
<dd><span class="Italics">Listeria monocytogenes</span></dd>
<dt> </dt>
<dd><span class="Italics">Staphylococcus aureus (resistant organisms may emerge during treatment)</span></dd>
<dt> </dt>
<dd><span class="Italics">Streptococcus pneumoniae</span></dd>
<dt> </dt>
<dd><span class="Italics">Streptococcus pyogenes</span></dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.5"></a><p></p>
<h3>Gram-negative Bacteria</h3>
<dl>
<dt> </dt>
<dd><span class="Italics">Bordetella <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">pertussis</span></span></dd>
<dt> </dt>
<dd><span class="Italics">Haemophilus influenzae</span></dd>
<dt> </dt>
<dd><span class="Italics">Legionella pneumophila</span></dd>
<dt> </dt>
<dd><span class="Italics">Neisseria gonorrhoeae</span></dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.6"></a><p></p>
<h3>Other Microorganisms</h3>
<dl>
<dt> </dt>
<dd><span class="Italics">Chlamydia trachomatis</span></dd>
<dt> </dt>
<dd><span class="Italics">Entamoeba histolytica</span></dd>
<dt> </dt>
<dd><span class="Italics">Mycoplasma pneumoniae</span></dd>
<dt> </dt>
<dd><span class="Italics">Treponema pallidum</span></dd>
<dt> </dt>
<dd><span class="Italics">Ureaplasma urealyticum</span></dd>
</dl>
<p class="First">The following data are available,
                                            <span class="Italics">in vitro</span><span class="Bold Underline">but their clinical significance is unknown.</span></p>
<p>At least 90% of the following bacteria exhibit <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentration</span> (MIC) less than or equal to the susceptible breakpoint for erythromycin. However, the efficacy of erythromycin in treating clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to these bacteria has not been established in adequate and well controlled clinical trials.
                                            <span class="Italics">in vitro</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.7"></a><p></p>
<h3>Gram-positive Bacteria</h3>
<dl>
<dt> </dt>
<dd><span class="Italics">Viridans group streptococci</span></dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.8"></a><p></p>
<h3>Gram-negative Bacteria</h3>
<dl>
<dt> </dt>
<dd><span class="Italics">Moraxella catarrhalis</span></dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.9"></a><p></p>
<h3>Susceptibility Test Methods</h3>
<p class="First">When available the clinical microbiology laboratory should provide the results of susceptibility test results for antimicrobial drug products used in resident hospitals to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports should aid the physician in selecting an antibacterial drug product for treatment.
                                            <span class="Italics">in vitro</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.9.1"></a><p></p>
<h4>Dilution Techniques</h4>
<p class="First">Quantitative methods are used to determine antimicrobial <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MIC's). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized test method (broth and/or agar). The MIC values should be interpreted according to criteria provided in .
                                                    <span class="Sup">1, 2</span><span class="Bold">Table 1</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.9.2"></a><p></p>
<h4>Diffusion techniques</h4>
<p class="First">Quantitative methods that require measurement of zone diameters can also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. The zone size provides an estimate of the susceptibility of bacteria to antimicrobial compounds. The zone size should be determined using a standardized test method. This procedure uses paper disks impregnated with 15 mcg erythromycin to test the susceptibility of microorganisms to erythromycin. The disc diffusion interpretive criteria are provided in .
                                                    <span class="Sup">2,3</span><span class="Bold">Table 1</span></p>
<a name="table1"></a><table width="75%">
<caption><span>Table 1. In Vitro Susceptibility Test Interpretive Criteria for Erythromycin</span></caption>
<col align="left" valign="top" width="22%">
<col align="center" valign="top" width="13%">
<col align="center" valign="top" width="13%">
<col align="center" valign="top" width="13%">
<col align="center" valign="top" width="13%">
<col align="center" valign="top" width="13%">
<col align="center" valign="top" width="13%">
<thead>
<tr class="First">
<th align="left"></th>
<th align="center" colspan="3" valign="bottom"><span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">Minimum Inhibitory Concentrations</span> (mcg/mL)
                                                                <br>
</th>
<th align="center" colspan="3" valign="bottom">Disk Diffusion (zone diameters in mm)
                                                                <br>
</th>
</tr>
<tr class="Last">
<th align="left">Pathogen</th>
<th align="center">S</th>
<th align="center">I</th>
<th align="center">R</th>
<th align="center">S</th>
<th align="center">I</th>
<th align="center">R</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td align="left" valign="middle">Staphylococcus aureus</td>
<td align="center" valign="middle">≤0.5</td>
<td align="center" valign="middle">1-4</td>
<td align="center" valign="middle">≥8</td>
<td align="center" valign="middle">≥23</td>
<td align="center" valign="middle">14-22</td>
<td align="center" valign="middle">≤13</td>
</tr>
<tr>
<td align="left" valign="middle">Streptococcus pneumoniae</td>
<td align="center" valign="middle">≤0.25</td>
<td align="center" valign="middle">0.5</td>
<td align="center" valign="middle">≥1</td>
<td align="center" valign="middle">≥21</td>
<td align="center" valign="middle">16-20</td>
<td align="center" valign="middle">≤15</td>
</tr>
<tr class="Last">
<td align="left" valign="middle">Streptococcus pyogenes</td>
<td align="center" valign="middle">≤0.25</td>
<td align="center" valign="middle">0.5</td>
<td align="center" valign="middle">≥1</td>
<td align="center" valign="middle">≥21</td>
<td align="center" valign="middle">16-20</td>
<td align="center" valign="middle">≤15</td>
</tr>
</tbody>
</table>
<p>A report of "Susceptible" indicates that the antimicrobial is likely to inhibit growth of the pathogen if the antimicrobial compound reaches the concentrations at the site of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> necessary to inhibit growth of the pathogen. A report of "Intermediate" indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug product is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of "Resistant" indicates that the antimicrobial is not likely to inhibit growth of the pathogen if the antimicrobial compound reaches the concentrations usually achievable at the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> site; other therapy should be selected.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.9.3"></a><p></p>
<h4>Quality Control</h4>
<p class="First">Standardized susceptibility test procedures require the use of laboratory controls to monitor and ensure the accuracy and precision of supplies and reagents used in the assay, and the techniques of the individuals performing the test. Standard erythromycin powder should provide the following range of MIC values noted in . For the diffusion technique using the 15 mcg disk, the criteria in should be achieved.
                                                    <span class="Sup">1, 2, 3, 4</span><span class="Bold">Table 2</span><span class="Bold">Table 2</span></p>
<a name="table2"></a><table width="75%">
<caption><span>Table 2. Acceptable Quality Control Ranges for Erythromycin</span></caption>
<col align="left" valign="top" width="33%">
<col align="center" valign="top" width="34%">
<col align="center" valign="top" width="33%">
<thead><tr class="First Last">
<th align="left" valign="bottom">QC <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">Strain</span></th>
<th align="center" valign="bottom"><span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">Minimum Inhibitory Concentrations</span> (mcg/mL)
                                                                <br>
</th>
<th align="center" valign="bottom">Disk Diffusion (zone diameters in mm)
                                                                <br>
</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="left">ATCC 29213
                                                                <span class="Italics">Staphylococcus aureus</span><br>
</td>
<td align="center" valign="middle">0.25-1</td>
<td align="center" valign="middle">NA</td>
</tr>
<tr>
<td align="left">ATCC 25923
                                                                <span class="Italics">Staphylococcus aureus</span><br>
</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">22-30</td>
</tr>
<tr>
<td align="left">ATCC 29212
                                                                <span class="Italics">Enterococcus faecalis</span><br>
</td>
<td align="center" valign="middle">1-4</td>
<td align="center" valign="middle">NA</td>
</tr>
<tr class="Last">
<td align="left">ATCC 49619
                                                                <span class="Italics">Streptococcus pneumoniae</span><br>
</td>
<td align="center" valign="middle">0.03-0.12</td>
<td align="center" valign="middle">25-30</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="IU"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">To reduce the development of drug-resistant bacteria and maintain the effectiveness of ERY-TAB and other antibacterial drugs, ERY-TAB should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
                            <span class="Sup">®</span><span class="Sup">®</span></p>
<p>ERY-TAB tablets are indicated in the treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the designated microorganisms in the diseases listed below:
                            <span class="Sup">®</span></p>
<p><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infections</span> of mild to moderate degree caused by ; ; (when used concomitantly with adequate doses of sulfonamides, since many <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.)
                            <span class="Italics">Streptococcus pyogenes</span><span class="Italics">Streptococcus pneumoniae</span><span class="Italics">Haemophilus influenzae</span><span class="Italics">H. influenzae</span></p>
<p><span class="product-label-link" type="condition" conceptid="4175297" conceptname="Lower respiratory tract infection">Lower respiratory tract infections</span> of mild to moderate severity caused by or .
                            <span class="Italics">Streptococcus pyogenes</span><span class="Italics">Streptococcus pneumoniae</span></p>
<p><span class="product-label-link" type="condition" conceptid="438059" conceptname="Listeriosis">Listeriosis</span> caused by .
                            <span class="Italics">Listeria monocytogenes</span></p>
<p><span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">Respiratory tract infections</span> due to .
                            <span class="Italics">Mycoplasma pneumoniae</span></p>
<p>Skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> of mild to moderate severity caused by or (resistant staphylococci may emerge during treatment).
                            <span class="Italics">Streptococcus pyogenes</span><span class="Italics">Staphylococcus aureus</span></p>
<p><span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">Pertussis</span> (whooping <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>) caused by . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals, rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">pertussis</span> in exposed susceptible individuals.
                            <span class="Italics">Bordetella <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">pertussis</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span>: <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> due to , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers.
                            <span class="Italics">Corynebacterium diphtheriae</span></p>
<p>Erythrasma: In the treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to .
                            <span class="Italics">Corynebacterium minutissimum</span></p>
<p>Intestinal <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span> caused by (oral erythromycins only). Extraenteric <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span> requires treatment with other agents.
                            <span class="Italics">Entamoeba histolytica</span></p>
<p>Acute <span class="product-label-link" type="condition" conceptid="199067" conceptname="Inflammatory disease of female pelvic organs AND/OR tissues">pelvic inflammatory disease</span> caused by : Erythrocin Lactobionate-I.V. (erythromycin lactobionate for injection, USP) followed by erythromycin base orally, as an alternative drug in treatment of acute <span class="product-label-link" type="condition" conceptid="199067" conceptname="Inflammatory disease of female pelvic organs AND/OR tissues">pelvic inflammatory disease</span> caused by in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span> before receiving erythromycin as treatment of <span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">gonorrhea</span> and a follow-up serologic test for <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span> after 3 months.
                            <span class="Italics">Neisseria gonorrhoeae</span><span class="Sup">®</span><span class="Italics">N. gonorrhoeae</span></p>
<p>Erythromycins are indicated for treatment of the following <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by : <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> of the newborn, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> of infancy, and urogenital <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in adults due to .
                            <span class="Italics">Chlamydia trachomatis</span><span class="Italics">Chlamydia trachomatis</span></p>
<p>When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal <span class="product-label-link" type="condition" conceptid="195862" conceptname="Urethritis">urethritis</span> caused by .
                            <span class="Italics">Ureaplasma urealyticum</span></p>
<p>Primary <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span> caused by . Erythromycin (oral forms only) is an alternative choice of treatment for primary <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span> in patients allergic to the penicillins. In treatment of primary <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span>, spinal fluid should be examined before treatment and as part of the follow-up after therapy.
                            <span class="Italics">Treponema pallidum</span></p>
<p>Legionnaires' Disease caused by . Although no controlled clinical efficacy studies have been conducted, and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease.
                            <span class="Italics">Legionella pneumophila</span><span class="Italics">in vitro</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1"></a><p></p>
<h2>Prophylaxis</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1.1"></a><p></p>
<h3>Prevention of Initial Attacks of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">Rheumatic Fever</span></h3>
<p class="First">Penicillin is considered by the American Heart Association to be the drug of choice in the prevention of initial attacks of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span> (treatment of Streptococcus pyogenes <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> of the upper respiratory tract e.g., <span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">tonsillitis</span>, or <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>). Erythromycin is indicated for the treatment of penicillin-allergic patients. The therapeutic dose should be administered for ten days.
                                            <span class="Sup">4</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1.2"></a><p></p>
<h3>Prevention of Recurrent Attacks of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">Rheumatic Fever</span></h3>
<p class="First">Penicillin or sulfonamides are considered by the American Heart Association to be the drugs of choice in the prevention of recurrent attacks of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span>. In patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the American Heart Association in the long-term prophylaxis of <span class="product-label-link" type="condition" conceptid="28060" conceptname="Streptococcal sore throat">streptococcal pharyngitis</span> (for the prevention of recurrent attacks of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span>).
                                            <span class="Sup">4</span></p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="contraindications"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Erythromycin is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to this antibiotic.</p>
<p>Erythromycin is contraindicated in patients taking terfenadine, astemizole, cisapride, pimozide, ergotamine, or dihydroergotamine. (See .)
                            <span class="Bold"><a href="#DI">PRECAUTIONS – Drug Interactions</a></span></p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="warnings"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1"></a><p></p>
<h2>Hepatotoxicity</h2>
<p class="First">There have been reports of hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or <span class="product-label-link" type="condition" conceptid="4318541" conceptname="Cholestatic hepatitis">cholestatic hepatitis</span>, with or without <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, occurring in patients receiving oral erythromycin products.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2"></a><p></p>
<h2>QT Prolongation</h2>
<p class="First">Erythromycin has been associated with prolongation of the QT interval and infrequent cases of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>. Cases of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span> have been spontaneously reported during postmarketing surveillance in patients receiving erythromycin. Fatalities have been reported. Erythromycin should be avoided in patients with known prolongation of the QT interval, patients with ongoing proarrhythmic conditions such as uncorrected <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> or <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>, clinically significant <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, and in patients receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents. Elderly patients may be more susceptible to drug-associated effects on the QT interval.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">Syphilis</span> in Pregnancy</h2>
<p class="First">There have been reports suggesting that erythromycin does not reach the fetus in adequate concentration to prevent <span class="product-label-link" type="condition" conceptid="434279" conceptname="Congenital syphilis">congenital syphilis</span>. Infants born to women treated during pregnancy with oral erythromycin for early <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span> should be treated with an appropriate penicillin regimen.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.4"></a><p></p>
<h2>Clostridium difficile Associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></h2>
<p class="First">associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents, including ERY-TAB , and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of .
                                    <span class="Italics">Clostridium difficile</span><span class="Sup">®</span><span class="Italics">C. difficile</span></p>
<p>produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.
                                    <span class="Italics">C. difficile</span><span class="Italics">C. difficile</span></p>
<p>If CDAD is suspected or confirmed, ongoing antibiotic use not directed against may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of , and surgical evaluation should be instituted as clinically indicated.
                                    <span class="Italics">C. difficile</span><span class="Italics">C. difficile</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.5"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Serious adverse reactions have been reported in patients taking erythromycin concomitantly with CYP3A4 substrates. These include colchicine toxicity with colchicine; <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> with simvastatin, lovastatin, and atorvastatin; and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> with calcium channel blockers metabolized by CYP3A4 (e.g., verapamil, amlodipine, diltiazem) (see ).
                                    <span class="Bold"><a href="#DI">PRECAUTIONS - Drug Interactions</a></span></p>
<p>There have been post-marketing reports of colchicine toxicity with concomitant use of erythromycin and colchicine. This interaction is potentially life-threatening, and may occur while using both drugs at their recommended doses (see ).
                                    <span class="Bold"><a href="#DI">PRECAUTIONS - Drug Interactions</a></span></p>
<p><span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span> with or without <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> has been reported in seriously ill patients receiving erythromycin concomitantly with lovastatin. Therefore, patients receiving concomitant lovastatin and erythromycin should be carefully monitored for creatine kinase (CK) and serum transaminase levels. (See package insert for lovastatin.)</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">Prescribing ERY-TAB in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
                                    <span class="Sup">®</span></p>
<p>Since erythromycin is principally excreted by the liver, caution should be exercised when erythromycin is administered to patients with impaired hepatic function. (See and .)
                                    <span class="Bold"><a href="#CP">CLINICAL PHARMACOLOGY</a></span><span class="Bold"><a href="#warnings">WARNINGS</a></span></p>
<p>Exacerbation of symptoms of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> and new onset of symptoms of <span class="product-label-link" type="condition" conceptid="4237155" conceptname="Eaton-Lambert syndrome">myasthenic syndrome</span> has been reported in patients receiving erythromycin therapy.</p>
<p>There have been reports of infantile hypertrophic <span class="product-label-link" type="condition" conceptid="4273754" conceptname="Pyloric stenosis">pyloric stenosis</span> (IHPS) occurring in infants following erythromycin therapy. In one cohort of 157 newborns who were given erythromycin for <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">pertussis</span> prophylaxis, seven neonates (5%) developed symptoms of non-<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">bilious vomiting</span> or <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> with feeding and were subsequently diagnosed as having IHPS requiring surgical pyloromyotomy. A possible dose-response effect was described with an absolute risk of IHPS of 5.1% for infants who took erythromycin for 8-14 days and 10% for infants who took erythromycin for 15-21 days. Since erythromycin may be used in the treatment of conditions in infants which are associated with significant mortality or morbidity (such as <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">pertussis</span> or neonatal Chlamydia trachomatis <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>), the benefit of erythromycin therapy needs to be weighed against the potential risk of developing IHPS. Parents should be informed to contact their physician if <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> with feeding occurs.
                                    <span class="Sup">5</span></p>
<p>Prolonged or repeated use of erythromycin may result in an overgrowth of nonsusceptible bacteria or fungi. If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occurs, erythromycin should be discontinued and appropriate therapy instituted.</p>
<p>When indicated, incision and drainage or other surgical procedures should be performed in conjunction with antibiotic therapy.</p>
<p>Observational studies in humans have reported cardiovascular malformations after exposure to drug products containing erythromycin during early pregnancy.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-7.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients should be counseled that antibacterial drugs including ERY-TAB should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When ERY-TAB is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by ERY-TAB or other antibacterial drugs in the future.
                                    <span class="Sup">®</span><span class="Sup">®</span><span class="Sup">®</span></p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="DI"></a><a name="section-7.3"></a><p></p>
<h2>Drug Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.1"></a><p></p>
<h3>Theophylline</h3>
<p class="First">Erythromycin use in patients who are receiving high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity. In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while the patient is receiving concomitant erythromycin therapy.</p>
<p>There have been published reports suggesting that when oral erythromycin is given concurrently with theophylline there is a decrease in erythromycin serum concentrations of approximately 35%. The mechanism by which this interaction occurs is unknown. The decrease in erythromycin concentrations due to co-administration of theophylline could result in subtherapeutic concentrations of erythromycin.</p>
<p><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>, <span class="product-label-link" type="condition" conceptid="4228448" conceptname="Bradyarrhythmia">bradyarrhythmias</span>, and <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> have been observed in patients receiving concurrent verapamil, belonging to the calcium channel blockers drug class.</p>
<p>Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.</p>
<p>There have been reports of increased anticoagulant effects when erythromycin and oral anticoagulants were used concomitantly. Increased anticoagulation effects due to interactions of erythromycin with oral anticoagulants may be more pronounced in the elderly.</p>
<p>Erythromycin is a substrate and inhibitor of the 3A isoform subfamily of the cytochrome p450 enzyme system (CYP3A). Coadministration of erythromycin and a drug primarily metabolized by CYP3A may be associated with elevations in drug concentrations that could increase or prolong both the therapeutic and adverse effects of the concomitant drug. Dosage adjustments may be considered, and when possible, serum concentrations of drugs primarily metabolized by CYP3A should be monitored closely in patients concurrently receiving erythromycin.</p>
<p>The following are examples of some clinically significant CYP3A based drug interactions. Interactions with other drugs metabolized by the CYP3A isoform are also possible. The following CYP3A based drug interactions have been observed with erythromycin products in post-marketing experience:</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.2"></a><p></p>
<h3>Ergotamine/dihydroergotamine</h3>
<p class="First">Post-marketing reports indicate that co-administration of erythromycin with ergotamine or dihydroergotamine has been associated with acute ergot toxicity characterized by <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> and <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> of the extremities and other tissues including the central nervous system. Concomitant administration of erythromycin with ergotamine or dihydroergotamine is contraindicated (see ).
                                            <span class="Bold"><a href="#contraindications">CONTRAINDICATIONS</a></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.3"></a><p></p>
<h3>Triazolobenzodiazepines (such as triazolam and alprazolam) and related benzodiazepines</h3>
<p class="First">Erythromycin has been reported to decrease the clearance of triazolam and midazolam, and thus, may increase the pharmacologic effect of these benzodiazepines.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.4"></a><p></p>
<h3>HMG-CoA Reductase Inhibitors</h3>
<p class="First">Erythromycin has been reported to increase concentrations of HMG-CoA reductase inhibitors (e.g., lovastatin and simvastatin). Rare reports of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> have been reported in patients taking these drugs concomitantly.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.5"></a><p></p>
<h3>Sildenafil (Viagra)</h3>
<p class="First">Erythromycin has been reported to increase the systemic exposure (AUC) of sildenafil. Reduction of sildenafil dosage should be considered. (See Viagra package insert.)</p>
<p>There have been spontaneous or published reports of CYP3A based interactions of erythromycin with cyclosporine, carbamazepine, tacrolimus, alfentanil, disopyramide, rifabutin, quinidine, methyl-prednisolone, cilostazol, vinblastine, and bromocriptine.</p>
<p>Concomitant administration of erythromycin with cisapride, pimozide, astemizole, or terfenadine is contraindicated. (See .)
                                            <span class="Bold"><a href="#contraindications">CONTRAINDICATIONS</a></span></p>
<p>In addition, there have been reports of interactions of erythromycin with drugs not thought to be metabolized by CYP3A, including hexobarbital, phenytoin, and valproate.</p>
<p>Erythromycin has been reported to significantly alter the metabolism of the nonsedating antihistamines terfenadine and astemizole when taken concomitantly. Rare cases of serious cardiovascular adverse events, including electrocardiographic QT/QT interval prolongation, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span>, and other <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span> have been observed. (See .) In addition, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> have been reported rarely with concomitant administration of terfenadine and erythromycin.
                                            <span class="Sub">c</span><span class="Bold"><a href="#contraindications">CONTRAINDICATIONS</a></span></p>
<p>There have been post-marketing reports of drug interactions when erythromycin was co-administered with cisapride, resulting in QT prolongation, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span>, <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span>, and <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span>, most likely due to the inhibition of hepatic metabolism of cisapride by erythromycin. Fatalities have been reported. (See .)
                                            <span class="Bold"><a href="#contraindications">CONTRAINDICATIONS</a></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.6"></a><p></p>
<h3>Colchicine</h3>
<p class="First">Colchicine is a substrate for both CYP3A4 and the efflux transporter P-glycoprotein (P-gp). Erythromycin is considered a moderate inhibitor of CYP3A4. A significant increase in colchicine plasma concentration is anticipated when co-administered with moderate CYP3A4 inhibitors such as erythromycin. If co-administration of colchicine and erythromycin is necessary, the starting dose of colchicine may need to be reduced, and the maximum colchicine dose should be lowered. Patients should be monitored for clinical symptoms of colchicine toxicity (see ).
                                            <a href="#warnings">WARNINGS</a></p>
</div>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="section-7.4"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<p class="First">Erythromycin interferes with the fluorometric determination of urinary catecholamines.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term oral dietary studies conducted with erythromycin stearate in rats up to 400 mg/kg/day and in mice up to about 500 mg/kg/day (approximately 1-2 fold of the maximum human dose on a body surface area basis) did not provide evidence of tumorigenicity. Erythromycin stearate did not show genotoxic potential in the Ames, and mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assays or induce chromosomal aberrations in CHO cells. There was no apparent effect on male or female fertility in rats treated with erythromycin base by oral gavage at 700 mg/kg/day (approximately 3 times the maximum human dose on a body surface area basis).</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.6"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-7.6.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.6.1.1"></a><p></p>
<h4>Pregnancy Category B</h4>
<p class="First">There is no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> or any other adverse effect on reproduction in female rats fed erythromycin base by oral gavage at 350 mg/kg/day (approximately twice the maximum recommended human dose on a body surface area) prior to and during mating, during gestation, and through weaning. No evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> or embryotoxicity was observed when erythromycin base was given by oral gavage to pregnant rats and mice at 700 mg/kg/day and to pregnant rabbits at 125 mg/kg/day (approximately 1-3 times the maximum recommended human dose).</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="section-7.7"></a><p></p>
<h2>Labor and Delivery</h2>
<p class="First">The effect of erythromycin on labor and delivery is unknown.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.8"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Erythromycin is excreted in human milk. Caution should be exercised when erythromycin is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.9"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">See and .
                                    <span class="Bold"><a href="#IU">INDICATIONS AND USAGE</a></span><span class="Bold"><a href="#DA">DOSAGE AND ADMINISTRATION</a></span></p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-7.10"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Elderly patients, particularly those with reduced renal or hepatic function, may be at increased risk for developing erythromycin-induced <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span>. (See and ).
                                    <span class="Bold"><a href="#AR">ADVERSE REACTIONS</a></span><span class="Bold"><a href="#DA">DOSAGE AND ADMINISTRATION</a></span></p>
<p>Elderly patients may be more susceptible to development of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span> <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> than younger patients. (See ).
                                    <span class="Bold"><a href="#warnings">WARNINGS</a></span></p>
<p>Elderly patients may experience increased effects of oral anticoagulant therapy while undergoing treatment with erythromycin. (See ).
                                    <span class="Bold"><a href="#DI">PRECAUTIONS - Drug Interactions</a></span></p>
<p>Ery-Tab Delayed Release Tablets (250 mg) contain 8.3 mg (0.4 mEq) of sodium per tablet.
                                    <span class="Sup">®</span></p>
<p>Ery-Tab Delayed Release Tablets (333 mg) contain 11.2 mg (0.5 mEq) of sodium per tablet.
                                    <span class="Sup">®</span></p>
<p>Ery-Tab Delayed Release Tablets (500 mg) contain 16.7 mg (0.7 mEq) of sodium per tablet.
                                    <span class="Sup">®</span></p>
<p>The geriatric population may respond with a blunted natriuresis to salt loading. This may be clinically important with regard to such diseases as <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="AR"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The most frequent side effects of oral erythromycin preparations are gastrointestinal and are dose-related. They include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>. Symptoms of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, hepatic dysfunction and/or abnormal liver function test results may occur. (See .)
                            <span class="Bold"><a href="#warnings">WARNINGS</a></span></p>
<p>Onset of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> symptoms may occur during or after antibacterial treatment. (See .)
                            <span class="Bold"><a href="#warnings">WARNINGS</a></span></p>
<p>Erythromycin has been associated with QT prolongation and <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>, including <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> and <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span>. (See ).
                            <span class="Bold"><a href="#warnings">WARNINGS</a></span></p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> ranging from <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> to <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> have occurred. <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin reactions</span> ranging from mild <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">eruptions</span> to <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> have been reported rarely.</p>
<p>There have been reports of interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span> coincident with erythromycin use.</p>
<p>There have been rare reports of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>.</p>
<p>There have been isolated reports of reversible <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span> occurring chiefly in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> and in patients receiving high doses of erythromycin.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">In case of overdosage, erythromycin should be discontinued. Overdosage should be handled with the prompt elimination of unabsorbed drug and all other appropriate measures should be instituted.</p>
<p>Erythromycin is not removed by peritoneal dialysis or hemodialysis.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="DA"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">In most patients, ERY-TAB (erythromycin delayed-release tablets) are well absorbed and may be dosed orally without regard to meals. However, optimal blood levels are obtained when ERY-TAB 250 mg, ERY-TAB 333 mg or ERY-TAB 500 mg tablets are given in the fasting state (at least 1/2 hour and preferably 2 hours before meals).
                            <span class="Sup">®</span><span class="Sup">®</span><span class="Sup">®</span><span class="Sup">®</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1"></a><p></p>
<h2>Adults</h2>
<p class="First">The usual dose is 250 mg four times daily in equally spaced doses. The 333 mg tablet is recommended if dosage is desired every 8 hours. If twice-a-day dosage is desired, the recommended dose is 500 mg every 12 hours. Dosage may be increased up to 4 g per day according to the severity of the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. However, twice-a-day dosing is not recommended when doses larger than 1 g daily are administered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2"></a><p></p>
<h2>Children</h2>
<p class="First">Age, weight, and severity of the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> are important factors in determining the proper dosage. The usual dosage is 30 to 50 mg/kg/day, in equally divided doses. For more severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, this dose may be doubled but should not exceed 4 g per day.</p>
<p>In the treatment of <span class="product-label-link" type="condition" conceptid="437779" conceptname="Streptococcal infectious disease">streptococcal infections</span> of the upper respiratory tract (e.g., <span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">tonsillitis</span> or <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>), the therapeutic dosage of erythromycin should be administered for at least ten days.</p>
<p>The American Heart Association suggests a dosage of 250 mg of erythromycin orally, twice a day in long-term prophylaxis of streptococcal <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infections</span> for the prevention of recurring attacks of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span> in patients allergic to penicillin and sulfonamides.
                                    <span class="Sup">4</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">Conjunctivitis</span> of the Newborn Caused by Chlamydia trachomatis</h2>
<p class="First">Oral erythromycin suspension 50 mg/kg/day in 4 divided doses for at least 2 weeks.
                                    <span class="Sup">4</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span> of Infancy Caused by Chlamydia trachomatis</h2>
<p class="First">Although the optimal duration of therapy has not been established, the recommended therapy is oral erythromycin suspension 50 mg/kg/day in 4 divided doses for at least 3 weeks.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.5"></a><p></p>
<h2>Urogenital <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> During Pregnancy Due to Chlamydia trachomatis</h2>
<p class="First">Although the optimal dose and duration of therapy have not been established, the suggested treatment is 500 mg of erythromycin by mouth four times a day or two erythromycin 333 mg tablets orally every 8 hours on an empty stomach for at least 7 days. For women who cannot tolerate this regimen, a decreased dose of one erythromycin 500 mg tablet orally every 12 hours, one 333 mg tablet orally every 8 hours or 250 mg by mouth four times a day should be used for at least 14 days.
                                    <span class="Sup">6</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.6"></a><p></p>
<h2>For adults with uncomplicated urethral, endocervical, or rectal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by Chlamydia trachomatis, when tetracycline is contraindicated or not tolerated</h2>
<p class="First">500 mg of erythromycin by mouth four times a day or two 333 mg tablets orally every 8 hours for at least 7 days.
                                    <span class="Sup">6</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.7"></a><p></p>
<h2>For patients with nongonococcal <span class="product-label-link" type="condition" conceptid="195862" conceptname="Urethritis">urethritis</span> caused by Ureaplasma urealyticum when tetracycline is contraindicated or not tolerated</h2>
<p class="First">500 mg of erythromycin by mouth four times a day or two 333 mg tablets orally every 8 hours for at least seven days.
                                    <span class="Sup">6</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.8"></a><p></p>
<h2>Primary <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">Syphilis</span></h2>
<p class="First">30 to 40 g given in divided doses over a period of 10 to 15 days.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.9"></a><p></p>
<h2>Acute <span class="product-label-link" type="condition" conceptid="199067" conceptname="Inflammatory disease of female pelvic organs AND/OR tissues">pelvic inflammatory disease</span> caused by N. gonorrhoeae</h2>
<p class="First">500 mg Erythrocin Lactobionate-I.V. (erythromycin lactobionate for injection, USP) every 6 hours for 3 days, followed by 500 mg of erythromycin base orally every 12 hours, or 333 mg of erythromycin base orally every 8 hours for 7 days.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.10"></a><p></p>
<h2>Intestinal <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">Amebiasis</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.10.1"></a><p></p>
<h3>Adults</h3>
<p class="First">500 mg every 12 hours, 333 mg every 8 hours or 250 mg every 6 hours for 10 to 14 days.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.10.2"></a><p></p>
<h3>Children</h3>
<p class="First">30 to 50 mg/kg/day in divided doses for 10 to 14 days.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.11"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">Pertussis</span></h2>
<p class="First">Although optimal dosage and duration have not been established, doses of erythromycin utilized in reported clinical studies were 40 to 50 mg/kg/day, given in divided doses for 5 to 14 days.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.12"></a><p></p>
<h2>Legionnaires' Disease</h2>
<p class="First">Although optimal dosage has not been established, doses utilized in reported clinical data were 1 to 4 g daily in divided doses.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.13"></a><p></p>
<h2>Preoperative Prophylaxis for Elective Colorectal Surgery</h2>
<p class="First">Listed below is an example of a recommended bowel preparation regimen.</p>
<p>A proposed surgery time of 8:00 a.m. has been used.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.13.1"></a><p></p>
<h3>Pre-op Day 3</h3>
<p class="First">Minimum residue or clear liquid diet. Bisacodyl, 1 tablet orally at 6:00 p.m.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.13.2"></a><p></p>
<h3>Pre-op Day 2</h3>
<p class="First">Minimum residue or clear liquid diet. Magnesium sulfate, 30 mL, 50% solution (15 g) orally at 10:00 a.m., 2:00 p.m. and 6:00 p.m. Enema at 7:00 p.m. and 8:00 p.m.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.13.3"></a><p></p>
<h3>Pre-op Day 1</h3>
<p class="First">Clear liquid diet. Supplemental (IV) fluids as needed. Magnesium sulfate, 30 mL, 50% solution (15 g) orally at 10:00 a.m. and 2:00 p.m. Neomycin sulfate (1.0 g) and erythromycin base (two 500 mg tablets, three 333 mg tablets or four 250 mg tablets) orally at 1:00 p.m., 2:00 p.m. and 11:00 p.m. No enema.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.13.4"></a><p></p>
<h3>Day of Operation</h3>
<p class="First">Patient evacuates rectum at 6:30 a.m. for scheduled operation at 8:00 a.m.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">NDC:68151-1174-1 in a PACKAGE of 1 TABLET, DELAYED RELEASES</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-11.1"></a><p></p>
<h2>Recommended Storage</h2>
<p class="First">Store below 86°F (30°C).</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-12"></a><p></p>
<h1>REFERENCES</h1>
<ol class="Arabic">
<li>Clinical and Laboratory Standards Institute (CLSI). CLSI document M07-A9, Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2012.
                                <span class="Italics">Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, Approved Standard – Ninth Edition.</span>
</li>
<li>Clinical and Laboratory Standards Institute (CLSI). CLSI document M100-S23, Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2013.
                                <span class="Italics">Performance Standards for Antimicrobial Susceptibility Testing: Twenty-third Informational Supplement.</span>
</li>
<li>Clinical and Laboratory Standards Institute (CLSI). CLSI document M02-A11. Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2012.
                                <span class="Italics">Performance Standards for Antimicrobial Disk Diffusion Susceptibility Tests; Approved Standard – Eleventh Edition</span>
</li>
<li>Committee on <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">Rheumatic Fever</span>, <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">Endocarditis</span>, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, the American Heart Association: Prevention of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">Rheumatic Fever</span>. Circulation. 78(4):1082-1086, October 1988.</li>
<li>Honein, M.A., et. al.: Infantile hypertrophic <span class="product-label-link" type="condition" conceptid="4273754" conceptname="Pyloric stenosis">pyloric stenosis</span> after <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">pertussis</span> prophylaxis with erythromycin: a case review and cohort study. The Lancet 1999:354 (9196): 2101-5.</li>
<li>Data on file, Arbor Pharmaceuticals, LLC.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13"></a><p></p>
<p class="First">03-A919-R2 Revised: July, 2013
                            <br></p>
<p>Arbor Pharmaceuticals, LLC Atlanta, GA 30328 USA
                            <br></p>
<p>(List 6304, 6320, 6321)</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-14"></a><p></p>
<h1>Erythromycin D.R.</h1>
<div class="Figure"><img alt="Label Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=83b88647-1b7c-444f-ab20-cdb5afd265bf&amp;name=68151-1174.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ERY-TAB 		
					</strong><br><span class="contentTableReg">erythromycin tablet, delayed release</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:68151-1174(NDC:24338-124)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Erythromycin</strong> (Erythromycin) </td>
<td class="formItem">Erythromycin</td>
<td class="formItem">333 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong><span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">AMMONIA</span></strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>DIACETYLATED MONOGLYCERIDES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE H)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE PHTHALATE (24% PHTHALATE, 55 CST)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CITRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SORBITAN MONOOLEATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">15mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">A;EH</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68151-1174-1</td>
<td class="formItem">1  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA062298</td>
<td class="formItem">04/18/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Carilion Materials Management
							(079239644)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Carilion Materials Management (079239644)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Carilion Materials Management</td>
<td class="formItem"></td>
<td class="formItem">079239644</td>
<td class="formItem">REPACK(68151-1174)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 5/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>a613594f-d5fe-4e88-9049-2b21824a061d</div>
<div>Set id: 83b88647-1b7c-444f-ab20-cdb5afd265bf</div>
<div>Version: 2</div>
<div>Effective Time: 20140501</div>
</div>
</div> <div class="DistributorName">Carilion Materials Management</div></p>
</body></html>
